Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following ...

The Bausch and Lomb Center honors two significant figures in the history of RIT; John J. Bausch and Captain Henry Lomb. With the outbreak of the Civil War in 1861, Henry Lomb enlisted with the ...

Amid swirling speculation, Bausch + Lomb (BLCO), a global leader in the contact lens supply industry, is reportedly exploring ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...

Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...